Before the widespread adoption of vaccination, adenovirus type 4 and type 7 were long associated with respiratory illnesses among military recruits. When supplies were depleted and vaccination was sus pended in 1999 for approximately a decade, respiratory illnesses due to adenovirus infections resurged. In March 2011, a new live, oral adenovirus vaccine was licensed by the US Food and Drug Administration and was first universally administered to military recruits in October 2011, leading to rapid, dramatic elimination of the disease within a few months. As part of licensure, a postmarketing study (Sentinel Surveillance Plan) was performed to detect potential safety signals within 42 days after immunization of military recruits. This study retrospectively evaluated possible adverse events related to vaccination using data from the Armed Forces Health Surveillance Branch Defense Medical Surveillance System (DMSS) database. Among 100,000 recruits who received the adenovirus vaccine, no statistically signifi cant greater risk of prespecified medical events was observed within 42 days after vaccination when compared with a historical cohort of 100,000 unvaccinated recruits. In an initial statistical analysis of International Classification of Disease, 9th Revision, Clinical Modification codes, a statistically significant higher risk for 19 other (not prespecified) medical events occurring in 5 or more recruits was observed among vaccinated compared with unvaccinated groups. After case record data abstraction for attribution and validation, two events (psoriasis [21 vs 7 cases] and serum reactions [12 vs 4 cases]) occurred more frequently in the vaccinated cohort. A causal relation of these rare events with adenovirus vaccination could not be established given confounding factors in the DMSS, such as coadministration of other vac cines and incomplete or inaccurate medical information, for some recruits. Prospective surveillance assessing these uncommon, but potentially relevant, immune-related symptoms may be beneficial in defining potential causal association with adenovirus vaccination.
© 2016 Published by Elsevier Ltd.
Introduction
Prior to the widespread use of adenovirus vaccine by the US military, adenovirus type 4 and type 7 accounted for approxi mately 60% of respiratory illnesses observed in hospitalized mili tary recruits. [1, 2] A live oral vaccine against adenovirus type 4 and type 7, introduced in the 1970s, was proven safe and effective, reducing adenovirus-associated respiratory illnesses by approxi mately 5.5-fold [1] .
Despite their efficacy, production of the vaccine by the sole manufacturer was discontinued in 1996, leading to rationing of 5.8 cases per 1000 person-weeks in 2000-2011 to 0.02 cases per 1000 person-weeks in 2012-2013) [6] .
Clinical data from phase 1 and 3 studies with military recruits have demonstrated that the new vaccine is safe. In a phase 1, ran domized double-blind, placebo-controlled study (N = 58), the most common adverse events (AEs) in the vaccinated group were nasal congestion (33%), cough (33%), sore throat (27%), headache (20%), abdominal pain (17%), arthralgia (13%), nausea (13%), and diarrhea (13%) [7] . The overall frequencies of AEs were similar to those in the placebo-treated arm [7] . In a phase 3, multicenter, randomized, double-blind, placebo-controlled study with military recruits (N = 4040), the incidence of AEs was comparable between vaccine and placebo arms [8] . No discontinuations due to AEs and no deaths were reported during the study [8] . Common (P10%) AEs associated with vaccination included upper respiratory tract infec tions (39%), headache (41%), nasal congestion (24%), pharyngo laryngeal pain (25%), cough (23%), arthralgia (26%), nausea (18%), abdominal pain (16%), and diarrhea (13%) [8] . Serious AEs were seen in 1% of both the vaccine and placebo arms. The most com mon serious AEs were psychiatric disorders and traumatic injuries.
The FDA mandated a postmarketing study (termed the Sentinel Surveillance Plan) to detect potential safety signals in military recruits exposed to this vaccine. The objective of this study was to assess the risk of medical events of interest or other events potentially related to administration of adenovirus type 4 and type 7 vaccine live, oral in a healthy US military population.
Methods

Study design
This study retrospectively evaluated possible AEs related to vac cination with adenovirus type 4 and type 7 vaccine live, oral using data coded based on the International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) and maintained as part of the Defense Medical Surveillance System (DMSS) database. The DMSS contains longitudinal health records for US military person nel including current and historical data on diseases, medical events, vaccination, and deployment history [9] . AE data were col lected for the vaccinated (hereafter referred to as exposed) cohort and a historical unvaccinated (hereafter referred to as unexposed) cohort of recruits from the previous year attending specific training sites for the Army (Fort Benning, GA; Fort Jackson, SC; Fort Leonard Wood, MO; Fort Sill, OK), Navy (Great Lakes Naval Training Center, Great Lakes, IL), Marine Corps (Parris Island, SC; San Diego, CA), and Air Force (Lackland Air Force Base, San Antonio, TX). The study was conducted under an institutional review board-granted waiver of informed consent.
Subjects
The exposed cohort consisted of healthy military recruits, 17-50 years of age, who received the live adenovirus type 4 and type 7 vaccine at the initiation of basic training at one of the spec ified training sites. The unexposed cohort comprised historically matched recruits who attended the same training site location dur ing the same month in the previous year; these individuals had the same vaccine requirements as the exposed group but did not receive the adenovirus vaccine.
Routine vaccinations
Adenovirus type 4 and type 7 vaccine, live, oral contains a lyo philized formulation of selected wild-type virus, with no fewer than 32,000 tissue-culture infective doses per enteric-coated tablet. Vaccine was administered orally as two tablets (one tablet each of type 4 and type 7), swallowed whole without chewing, at the beginning of basic training. The following additional manda tory vaccines were routinely administered to military recruits without contraindications within their first week of basic training (mandatory vaccines may vary by installation): meningococcal, inactivated polio, tetanus-diphtheria-acellular pertussis, influenza (inactivated or live attenuated), pneumococcal (when indicated per Service policy), typhoid inactivated (when indicated per Ser vice policy), and yellow fever (when indicated per Service policy). Recruits testing seronegative for measles, rubella, varicella, or hep atitis A or B were also vaccinated against these viruses. In addition, female recruits were offered the human papillomavirus vaccine per Service policy. (Fig. 1) Adverse medical events occurring among recruits were identi fied through routine health encounters and were coded by the health personnel at the training sites according to ICD-9-CM and entered into the DMSS. Reported events that occurred within 42 days following administration of adenovirus vaccine or initial mandatory vaccines during basic training were collected for each individual in the exposed and unexposed cohorts.
Data collection and extraction
Adverse medical events were classified as ''prespecified AEs of interest" or ''cohort-associated AEs." Prespecified AEs of interest were determined by the study sponsor (including the Department of Defense) in discussion with the FDA prior to study initiation as medically important and potentially related to adenovirus vaccina tion (Table 1) . Cohort-associated AEs were defined as any events (prespecified or otherwise) occurring at a statistically significant higher incidence rate (as determined using the Poisson regression model with two-tailed statistical testing conducted at a 5% signif icance level) in the exposed cohort compared with the unexposed cohort. Because of the nonspecific nature of some cohortassociated event codes at the ICM-9-CM 3-digit classification level, data were also collected at the 4-to 5-digit subcode level for all cohort-associated event codes that reached statistical significance at the 3-digit level. Cohort-associated events were captured using only data entered into the primary diagnostic code position for a particular health encounter (eg, events coded in 2nd to 8th diag nostic code positions were not considered).
The contract research organization (CRO) medical monitor con ducted a medical review to determine if there was a plausible bio logical relationship between each potential cohort-associated ICD 9-CM event code and the vaccine. The scientific review committee (SRC) conducted an independent review and made recommenda tions for the inclusion of selected cohort-associated medical event codes as emergent events of interest, defined as possibly related to the adenovirus vaccination, unexpected, and clinically important.
The CRO medical monitor, in consultation with the Immuniza tion Healthcare Branch at the Defense Health Agency further vali dated prespecified medical events and/or emergent events of interest by reviewing abstracted available medically relevant infor mation from the individual records of subjects who experienced the events using a standardized data-abstraction form. During abstraction, data were captured using ICD-9-CM event codes listed in any diagnostic code position. Data (personal identifiable infor mation redacted) abstracted from medical records included, as available, details of each report of the medical event of interest; hospital admissions related to the event; acute and chronic condi tions; AEs occurring within 42 days of vaccination, excluding pre specified events of interest; alcohol, recreational drug, and tobacco use; and use of other medications and nondrug therapies. The completed abstraction forms were reviewed and approved by the Department of Defense principal investigator to ensure Other and unspecified adverse effect of drug, medicinal and biological substance (due) to correct medicinal substance properly administered 999. 4 Anaphylactic shock due to serum, NEC ICD-9-CM = International Classification of Disease, 9th Revision, Clinical Modifica tion; NEC = not elsewhere classified. completeness, to the extent possible, and appropriateness of the abstracted data before release. For certain codes where large num bers of events were reported, a random sample of the correspond ing records was abstracted per recommendation by the SRC. Following abstraction, some events were rejected as related to vac cination for any of the following reasons: (1) the event occurred outside of the relevant exposure window; (2) confirmed laboratory findings indicated that the medical event occurred prior to vacci nation; (3) the event was due to a preexisting condition without evidence of an acute event related to vaccination; and, (4) there was a lack of documentation for a clinical syndrome or expected treatment consistent with the event term. Table 2 Demographics of cohorts at screening.
Exposed cohort a n (%) Unexposed cohort a n (%) a Exposed and unexposed cohort each has a total of 100,000 recruits.
Statistical methods
The final cumulative analysis was planned and performed after 100,000 matched recruits had accrued in the exposed cohort. A sample size of 200,000 (100,000 per cohort) was expected to pro vide more than 80% power to detect a 2-fold increase in preva lence, assuming an event was present in at least 0.024% of the unexposed cohort, and a two-sided alpha of 0.05.
Analyses of prespecified and emergent medical events of inter est were conducted by calculating the incidence rate for each cohort and determining the risk ratio. Incidence rate was defined as the total number of subjects experiencing a specific event code for the first time during the study period divided by person-years at risk among recruits over the same period. Person-years were estimated using the number of recruits and 42 days following 4 Anaphylactic shock, serum 0 3 --(26.09) CI = confidence interval; ICD-9-CM = International Classification of Disease, 9th Revision, Clinical Modification. Incidence rate (IR) per 100,000 person-years (P-Y) of exposure (IR/100,000 P-Y) = event ⁄ 100,000/P-Y of exposure; risk ratio (RR) = IR exposed/IR unexposed. Event codes listed in bold were selected for abstraction investigation as emergent events of interest. vaccination (0.1150 years) as the period. The risk ratio was defined as the ratio of the exposed versus unexposed incidence rates. Cohort-associated events were identified using a Poisson regres sion model with two-tailed statistical testing conducted at a 5% significance level.
Results
Study subjects
Adenovirus vaccination was begun on October 24, 2011, and the final exposed recruit was vaccinated on October 5, 2012. Data from a total of 200,000 recruits (100,000 in each cohort) were evaluated for this study, with an estimated 11,499 person-years for each cohort.
The demographic characteristics were similar for the exposed and unexposed cohorts, indicating that the two groups were com parable ( Table 2) . In both groups, 84% of subjects were male; distri bution by race/ethnicity was also similar between the exposed and unexposed cohorts. Ages at first vaccination ranged from 17 to 50 years. The Army accounted for the greatest proportion of study subjects in each cohort, followed by the Air Force, the Marine Corps, and the Navy.
Prespecified medical events of interest
A total of 3474 and 4789 prespecified medical events of interest (including ICD-9-CM event codes listed in any diagnostic code position) were experienced by the exposed and unexposed cohorts, respectively ( Table 3) . None of the prespecified medical events was found to be statistically more frequent in the exposed group, com pared to the unexposed group. A significant reduction in risk was observed in the vaccinated cohort for epilepsy, pneumonia (organ ism unspecified), syncope and collapse, and rash and other non specific skin eruption (limited to hospitalization). According to protocol, however, these cases were not verified by abstraction because of the reduced risk associated with these events. The reduction in risk could not be calculated for viral pneumonia, pneumonia due to adenovirus, or anaphylactic shock due to serum, because no cases were reported in the exposed cohort.
A total of 103 patient cases were abstracted, including 59 in the exposed cohort and 44 in the unexposed (Table 4 ). In addition, despite the lack of statistically significant findings, medical records for seven codes of rare and/or serious events were recommended for abstraction. Abstraction of these seven events identified four that were possibly related to adenovirus vaccination: 323.52 (myelitis, n = 1), 420.9 (pericarditis, n = 1), 357.0 (acute infective polyneuritis, n = 2), and 995.0 (other anaphylactic shock, not elsewhere classified, n = 3); however, in all instances, other vaccines were coadminis cohort-associated events were selected as emergent events of tered and could not be ruled out as having contributed to the events.
interest for further investigation and abstraction (Table 6 ). The data from the abstractions did not indicate any definitive biological or clinical associations with adenovirus vaccination.
3.4. Emergent events of interest 3.3. Cohort-associated medical events A total of 1624 and 974 emergent events of interest in seven codes were experienced by the exposed and unexposed cohorts, There were 19 cohort-associated medical events with statistirespectively. Most events were recorded at Lackland Air Force Base cally significant higher risk ratios in the exposed cohort versus and Great Lakes Naval Training Center. Medical information the unexposed cohort described at the 3-digit ICD-9-CM code level related to these events from 292 subjects was abstracted for vali and the 4-and 5-digit subcode levels (Table 5 ). Based on dation including 221 from the exposed cohort and 71 from the SRC review of the data and medical evaluations, seven unexposed cohort. In the case of three ICD-9-CM events that Incidence rate (IR) per 100,000 person-years (P-Y) of exposure (IR/100,000 P-Y) = event ⁄ 100,000/P-Y of exposure; risk ratio (RR) = IR exposed/IR unexposed.
occurred predominantly at a single base, abstraction of a 10% ran dom sampling of code 282.2 (anemias due to disorders of glu tathione), 282.5 (sickle cell trait), and 285.9 (anemia unspecified) was performed on subjects from the Lackland Air Force Base and Great Lakes Naval Training Center (see Table 6 for events by base). A summary of the cases validated and considered related is pre sented in 
Discussion and conclusion
A statistically significant higher risk for 19 medical event codes was detected in the DMSS database among recruits who received the adenovirus type 4 and type 7 vaccine (exposed) compared with unvaccinated (unexposed) recruits. None of the prespecified med ical event codes was found to be statistically more frequent in the exposed cohort than in the unexposed cohort, although anaphylac tic shock (code 995.0) approached significance (risk ratio = 1.59, 95% confidence interval 1.00-2.52). For most of the cohortassociated events, the SRC determined that there was no biologi cally plausible explanation for the increased frequency in the vac cinated cohort. In general, these events were associated with factors related to demography (eg, preponderance of an event by gender or race) and/or geography (eg, concentration of an event at a particular military base). However, seven events were consid ered emergent events of interest and six were validated through abstraction of medical records. Of the six validated events, only two (696.1-psoriasis and 999.5-serum reactions) had events that were considered possibly related to vaccination. Despite the statis tically significant association between these event codes and vac cine exposure, the true relationship between the occurrence of the event and administration of the adenovirus vaccine cannot be evaluated based on the statistical results alone.
The retrospective nature of this study limits interpretation of the relationship between the adenovirus vaccine and the few events that occurred during the 42-day postvaccination period. The military recruit population, by its nature, limits the impact of confounding variables such as age and health status. Variability of reporting and differences in the experience and training of medical personnel at the basic training sites, as well as limitations of the DMSS database such as loss to follow-up due to discharge from the military, reduce the ability to distinguish a genuine safety signal associated with the adenovirus vaccine from other con tributing factors.
For these reasons, the potential causes of the observed increases in psoriasis, anaphylaxis, and other hypersensitivity reactions are unclear. Prospective surveillance assessing these uncommon, but potentially relevant, immune-related symptoms may be beneficial in defining potential causal association with adenovirus vaccination.
It should be highlighted that, subsequent to the institution of adenovirus vaccination and conduct of this study, US military investigators have also noted a reduction in adenovirus associated respiratory illnesses; these findings are consistent with the beneficial effects described in earlier reports [1, 3, 4, 6] .
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